Overview

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Status:
Recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

ALX Oncology Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Carboplatin
Pembrolizumab